Independent reviews of supplements & peptides
Straight answers about what’s actually worth taking.
We read the primary research so you don’t have to guess — then we give you a clear verdict, with every claim cited to its source.
- Every claim cited to primary research
- 100% independent — nothing for sale
- Reviewed by humans, updated weekly
Every review ends in a verdict.
Five plain-English calls — no hedging.
24 guides · Updated weekly
Supplement guides
Is it worth it, oversold, or still unsettled? Clear verdicts on the supplements you actually see — magnesium, creatine, fish oil, ashwagandha — each backed by a full source list.
9 dossiers · Regulation tracked weekly
The peptide desk
Heard about BPC-157 or compounded semaglutide on a podcast? Plain-English dossiers on what the research actually shows, plus fact-checks of viral claims and a weekly read on FDA moves.
Fresh this week
All updates →PCAC ~Feb 2027 — reported second 503A peptide batch
Bakri on Huberman Lab — the animal-to-human evidence gap
For BPC-157 there is a large gap between the animal research and human clinical evidence, and a key safety concern is that BPC-157 upregulates VEGF to promot…
'Compounded semaglutide is the same as Ozempic'
Compounded semaglutide is the same as Ozempic or Wegovy — identical drug, just cheaper — so there's no meaningful difference in getting it from a compounder.
'Removed from Category 2 means BPC-157 is legal to compound/buy now'
Because the FDA removed BPC-157 from the Category 2 "do not compound" list in April 2026, it is now legal for compounding pharmacies to prepare it and for co…